Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Ocugen, Inc.
  6. News
  7. Summary
    OCGN   US67577C1053

OCUGEN, INC.

(OCGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

OCUGEN INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Ocugen, Inc. - OCGN

09/10/2021 | 10:51pm EDT

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Ocugen, Inc. (NasdaqCM: OCGN).

On June 10, 2021, the Company disclosed that it would pursue a “biologics license application” with the U.S. Food and Drug Administration for its COVID-19 vaccine candidate/product rather than the Emergency Use Authorization process that it had previously stated it would utilize.

The Company has been sued in a securities class action lawsuit for failing to disclose material information, violating federal securities laws, which is ongoing.

KSF’s investigation is focusing on whether Ocugen’s officers and/or directors breached their fiduciary duties to Ocugen’s shareholders or otherwise violated state or federal laws.

If you have information that would assist KSF in its investigation, or have been a long-term holder of Ocugen shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqcm-ocgn/ to learn more.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking to recover investment losses due to corporate fraud and malfeasance by publicly traded companies. KSF has offices in New York, California, Louisiana and New Jersey.

To learn more about KSF, you may visit www.ksfcounsel.com.


ę Business Wire 2021
All news about OCUGEN, INC.
10/21INSIDER SELL : Ocugen
MT
10/19OCUGEN INC : . to present pre-clinical data for OCU410 at 2nd Annual Dry AMD Therapeutic D..
AQ
10/16OCUGEN INC : . Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
10/15INSIDER SELL : Ocugen
MT
10/15OCUGEN : Thinking about buying stock in Plug Power, Cemtrex, Ocugen, NRX Pharmaceuticals, ..
PR
10/14SOCIAL BUZZ : Ocugen, AMC, BlackBerry Top WallstreetBets Stock Gainers at Thursday Close
MT
10/14SOCIAL BUZZ : BlackBerry Seeing Late Day Strength
MT
10/13SOCIAL BUZZ : Plug Power Surges, Ocugen Slides
MT
10/12CLOSE UPDATE : US Stocks Waver Ahead of Earnings, FOMC Minutes; Investors Remain Cautious ..
MT
10/12SOCIAL BUZZ : Wallstreetbets Top Stocks Ocugen, SoFi, Tesla Gain as Broader Market Slides
MT
More news
Analyst Recommendations on OCUGEN, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -55,4 M - -
Net Debt 2021 - - -
P/E ratio 2021 -29,0x
Yield 2021 -
Capitalization 1 654 M 1 654 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 9,15x
Nbr of Employees 15
Free-Float 97,5%
Chart OCUGEN, INC.
Duration : Period :
Ocugen, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OCUGEN, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 8,32 $
Average target price 8,88 $
Spread / Average Target 6,67%
EPS Revisions
Managers and Directors
Shankar Musunuri Chairman & Chief Executive Officer
Sanjay Subramanian CFO, Secretary & Head-Corporate Development
Arun Upadhyay Vice President-Research & Development
Bruce D. Forrest Chief Medical Officer
Uday B. Kompella Independent Director
Sector and Competitors
1st jan.Capi. (M$)
OCUGEN, INC.354.64%1 654
MODERNA, INC.212.57%131 807
LONZA GROUP AG32.74%61 177
IQVIA HOLDINGS INC.43.38%49 076
SEAGEN INC.-2.12%31 189
CELLTRION, INC.-38.86%25 455